Pannysylvania Magazine

DelveInsight’s, “Primary Biliary Cholangitis Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape. It covers the Primary Biliary Cholangitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Primary Biliary Cholangitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Primary Biliary Cholangitis Pipeline? @ https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pipeline-insight

Key Takeaways from the Primary Biliary Cholangitis Pipeline Report

• On June 23, 2026- Gilead Sciences initiated a study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
• On June 22, 2026- GlaxoSmithKline announced a study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620 GLISTEN [NCT00210418]) (group 2).
• On June 10, 2026- Umecrine Cognition AB conducted a research study are to assess the safety and tolerability as well the pharmacokinetic (PK) characteristics of golexanolone administered 40 mg BID for 5 days in the target population (part A) and to assess the safety and tolerability, the effects of golexanolone on health-related quality of life (HRQoL), including fatigue, day-time sleepiness and cognitive function as well as Investigator’s overall impression of treatment effect of 28 days twice per day (BID) treatment with two dose levels of golexanolone versus placebo (part B).
• On June 08, 2026- Ipsen announced a study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC) during the double-blind period, an initial 96 week open-label extension (OLE) period, and an optional open-label extension long-term (OLE-LT) period beyond OLE Week 96. PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment.
• DelveInsight’s Primary Biliary Cholangitis Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Primary Biliary Cholangitis treatment.
• The leading Primary Biliary Cholangitis Companies such as Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline and others.
• Promising Primary Biliary Cholangitis Therapies such as Saroglitazar Magnesium 1 mg, Seladelpar, ASC42 5 mg, Elafibranor, Obeticholic Acid Tablets, Bezafibrate 100 mg, Obeticholic Acid 5 mg and others.

Want to know which companies are leading innovation in Primary Biliary Cholangitis? @ Primary Biliary Cholangitis Clinical Trials Assessment

The Primary Biliary Cholangitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Primary Biliary Cholangitis Pipeline Report also highlights the unmet needs with respect to the Primary Biliary Cholangitis.

Primary Biliary Cholangitis Overview

Primary Biliary Cholangitis (PBC) is a chronic, progressive autoimmune disease that primarily affects the bile ducts in the liver. It leads to inflammation and gradual destruction of the small bile ducts, causing bile to accumulate in the liver (cholestasis). Over time, this can result in liver damage, fibrosis, and eventually cirrhosis. Although the exact cause of PBC remains unclear, it predominantly affects middle-aged women and is considered an autoimmune disorder. Genetic and environmental factors, such as infections or toxic exposures, may contribute to its onset.

Primary Biliary Cholangitis Emerging Drugs Profile

• Saroglitazar Magnesium: Zydus Therapeutics

Saroglitazar (LIPAGLYN) contains two main classes of PPAR agonists, which include PPARα (alpha) and PPARγ (gamma). The drug has lipid and glucose-lowering effects in a single molecule; it lowers high blood triglycerides and blood sugar and improves insulin resistance. The drug is available in tablet form of 4 mg dose for oral administration. Saroglitazar is indicated for treating diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated a reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, and non-HDL cholesterol and an increase in HDL cholesterol, a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). The US FDA has granted ODD and FTD to saroglitazar Mg for PBC. It is currently being investigated in Phase III stage of clinical development for the treatment of Primary Biliary Cholangitis.

• Setanaxib: Calliditas Therapeutics

Setanaxib (GKT831), a NOX1 and NOX4 inhibitor, has shown evidence of anti-fibrotic activity in a Phase II clinical trial in primary biliary cholangitis (PBC, an orphan liver disease). Based on its Phase II results, a phase II/III trial with Setanaxib in PBC was initiated. Setanaxib is also being evaluated in an investigator-initiated Phase II clinical trial in Type 1 Diabetes and Kidney Disease (DKD) as well as being studied in an investigator led Phase II clinical trial in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that results in fibrosis of the lungs. Currently the drug is in Phase II stage of its development for the treatment of Primary biliary cholangitis.

• HPG-1860: Hepagene

HPG-1860 is under development for the treatment of non-alcoholic steatohepatitis (NASH), Primary Biliary Cholangitis. It is administered by oral route. The drug candidate is an avermectin derivative and acts by targeting farnesoid X activated receptor. The drug is currently in phase I stage of development for the treatment of PBC. The drug is currently in Phase I stage of its clinical development for the study of Primary Biliary Cholangitis (PBC).

If you’re tracking ongoing Primary Biliary Cholangitis Clinical trials, this press release is a must-read @ Primary Biliary Cholangitis Treatment Drugs

Primary Biliary Cholangitis Companies

Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline and others.

Primary Biliary Cholangitis (PBC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Primary Biliary Cholangitis Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Primary Biliary Cholangitis Pipeline Report covers it all @ Primary Biliary Cholangitis Market Drivers and Barriers, and Future Perspectives

Scope of the Primary Biliary Cholangitis Pipeline Report

• Coverage- Global
• Primary Biliary Cholangitis Companies- Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline and others.
• Primary Biliary Cholangitis Therapies- Saroglitazar Magnesium 1 mg, Seladelpar, ASC42 5 mg, Elafibranor, Obeticholic Acid Tablets, Bezafibrate 100 mg, Obeticholic Acid 5 mg and others.
• Primary Biliary Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Primary Biliary Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Primary Biliary Cholangitis treatment landscape in this detailed analysis @ Primary Biliary Cholangitis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Primary Biliary Cholangitis (PBC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Primary Biliary Cholangitis (PBC)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Saroglitazar Magnesium: Zydus Therapeutics
9. Mid Stage Products (Phase II)
10. Setanaxib: Calliditas Therapeutics
11. Early Stage Products (Phase I)
12. HPG-1860: Hepagene
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Primary Biliary Cholangitis (PBC) Key Companies
17. Primary Biliary Cholangitis (PBC) Key Products
18. Primary Biliary Cholangitis (PBC)- Unmet Needs
19. Primary Biliary Cholangitis (PBC)- Market Drivers and Barriers
20. Primary Biliary Cholangitis (PBC)- Future Perspectives and Conclusion
21. Primary Biliary Cholangitis (PBC) Analyst Views
22. Primary Biliary Cholangitis (PBC) Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/primary-biliary-cholangitis-pipeline-insight